GlaxoSmithKline (GSK) Diabetes Drug Fails Head-to-head Against Victoza  
11/16/2011 6:46:05 AM

GlaxoSmithKline’s long-acting diabetes drug albiglutide has failed in a head-to-head trial against Novo Nordisk’s Victoza. Albiglutide is an injectable glucagon-like peptide-1 (GLP-1) agonist currently undergoing Phase III trials to help type II diabetes patients reduce their blood sugar levels after they have failed on oral treatments.